Health
Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers – OncLive
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant…
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib (AMG 510) and adagrasib in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting.1,2
The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases…
-
Business20 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General21 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General20 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News15 hours agoNoosa International Surfilm Festival 2025 program revealed